Ionis Pharmaceuticals Inc

NASDAQ: IONS
$39.19
+$0.73 (+1.9%)
Closing Price on November 8, 2024

IONS Stock Chart and Intraday Price

IONS Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 2855 GAZELLE COURT, CARLSBAD, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 6,625.89M USD
Shares Outstanding 145,752,000
Ionis Pharmaceuticals Inc is a pioneer in creating RNA-targeted therapeutics. With a focus on serious and rare diseases, it has brought to market treatments like SPINRAZA for spinal muscular atrophy and TEGSEDI for polyneuropathy caused by hereditary transthyretin amyloidosis. The company is also advancing a robust pipeline of medicines targeting conditions such as amyotrophic lateral sclerosis, cardiovascular disease, and hepatitis B, among others. Ionis collaborates with leading pharmaceutical companies to enhance its reach and impact. Based in Carlsbad, California, Ionis continues to push the boundaries of medical science.

IONS Articles

Tuesday's top analyst upgrades and downgrades included BioNTech, ConocoPhillips, Harley-Davidson, Livent, Luminar Technologies, Meta Platforms, Moderna, Snap, Twitter, United Airlines, US Foods,...
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Etsy, Fate Therapeutics, Intellia, Ionis, Monster Beverage and more.
Akcea Therapeutics stock jumped on Monday after it was announced that Ionis Pharmaceuticals would be acquiring all of its outstanding shares.
Akcea Therapeutics and Ionis Pharmaceuticals each made handy gains on Wednesday after the firms reported midstage results for their cardiovascular disease study.